Skip to Content
  1. Authors
  2. Karen Andersen

Karen Andersen

Karen Andersen, CFA, is a healthcare strategist for Morningstar.


Management raised its product sales guidance for 2020 by a range of $1.2-$2.8 billion after incorporating coronavirus headwinds and highly uncertain sales assumptions for remdesivir. This guidance fits with our assumption of $2 billion in remdesivir sales in 2020, and we're maintaining our $85 per share fair value estimate for the firm.